Early use of intravenous methylprednisolone is associated with attenuation of drug challenge reactions in patients with severe cutaneous adverse drug reactions
- 17 September 2026
- journal article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
Abstract
No abstract availableFunding Information
- European Commission (TMA2017SF-1981)
- National Institute of Allergy and Infectious Diseases (R01AI152183)
- South African Medical Research Council
- National Research Foundation
- Fogarty International Center (K43TW011178-04)
This publication has 7 references indexed in Scilit:
- Management of patients with tuberculosis medication-induced drug reaction with eosinophilia and systemic symptomsCurrent Opinion in Allergy and Clinical Immunology, 2025
- Utility of IFN-γ Enzyme-Linked Immunospot as Adjunctive Diagnostic for Severe T Cell–Mediated Reactions to Cotrimoxazole in High HIV and Tuberculosis SettingsThe Journal of Allergy and Clinical Immunology: In Practice, 2025
- First-Line Antituberculosis Drug Challenge Reactions in Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome in an HIV Endemic SettingThe Journal of Allergy and Clinical Immunology: In Practice, 2024
- Severe cutaneous adverse reactionsNature Reviews Disease Primers, 2024
- Early high-dose intravenous corticosteroids rapidly arrest Stevens Johnson syndrome and drug reaction with eosinophilia and systemic symptoms recurrence on drug re-exposureThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?The Journal of Allergy and Clinical Immunology: In Practice, 2020
- Cost of managing severe cutaneous adverse drug reactions to first‐line tuberculosis therapy in South AfricaTropical Medicine & International Health, 2019